Astria Therapeutics
Amneal Pharmaceuticals

Harrow to Present at Two Investor Conferences in May

May 15, 2024 | Last Trade: US$17.89 0.39 2.23

NASHVILLE, Tenn. / May 15, 2024 / Business Wire / Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in the following two investor conferences in May:

B. Riley Securities 24th Annual Institutional Investor Conference (Beverly Hilton Hotel, Beverly Hills, CA)
Format: Fireside Chat (In-Person), followed by 1x1 Investor Meetings
Date/Time: Wednesday, May 22, 2024, through Thursday, May 23, 2024

Craig-Hallum 21st Annual Institutional Investor Conference (Depot Renaissance Hotel, Minneapolis, MN)
Format: 1x1 and Small Group Investor Meetings
Date/Time: Wednesday, May 29, 2024

Investors interested in meeting with management during either conference should contact their B. Riley or Craig-Hallum representative to request a meeting. Neither event will be webcast.

About Harrow

Harrow, Inc. (Nasdaq: HROW) is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the North American market. Harrow helps eyecare professionals preserve the gift of sight by making its portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of patients each year. For more information about Harrow, please visit harrow.com.


Stock Quote

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...


Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...


End of content

No more pages to load

Next page